This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hansen, J. E. Articles by Reeves, M. E. Search for Related Content PubMed PubMed Citation Articles by Hansen, J. E. Articles by Reeves, M. E.

Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivo

¹ Veterans Affairs Greater Los Angeles Healthcare System, Sepulveda, California; ² Loma Linda Veterans Affairs Medical Center; ³ Loma Linda University, Loma Linda, California; ⁴ Olive View-University of California at Los Angeles Medical Center, Sylmar, California; and ⁵ University of California at Los Angeles David Geffen School of Medicine, Los Angeles, California

Requests for reprints: Richard H. Weisbart, Veterans Affairs Medical Center (111S), 16111 Plummer Street, Sepulveda, CA 91343. Phone: 818-895-9384; Fax: 818-895-9423; E-mail: rweisbar{at}ucla.edu.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
To evaluate the clinical efficacy of monoclonal antibody (mAb) 3E10 Fv antibody-mediated p53 protein therapy, an Fv-p53 fusion protein produced in Pichia pastoris was tested on CT26.CL25 colon cancer cells in vitro and in vivo in a mouse model of colon cancer metastasis to the liver. In vitro experiments showed killing of CT26.CL25 cells by Fv-p53 but not Fv or p53 alone, and immunohistochemical staining confirmed that Fv was required for transport of p53 into cells. Prevention of liver metastasis in vivo was tested by splenic injection of 100 nmol/L Fv-p53 10 min and 1 week after injection of CT26.CL25 cancer cells into the portal vein of BALB/c mice. Mice were sacrificed 1 week after the second injection of Fv-p53 and assigned a quantitative metastasis score. Control mice had an average metastasis score of 3.3 ± 1.3, whereas mice treated with Fv-p53 had an average metastasis score of 0.8 ± 0.4 (P = 0.004). These results indicate that Fv-p53 treatment had a profound effect on liver metastasis and represent the first demonstration of effective full-length p53 protein therapy in vivo. mAb 3E10 Fv has significant clinical potential as a mediator of intracellular and intranuclear delivery of p53 for prevention and treatment of cancer metastasis. [Cancer Res 2007;67(4):1769–74]

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Often referred to as the guardian of the genome, p53 plays a critical role in tumor suppression. Defects in p53 are linked to >50% of human cancers, and numerous studies have shown that restoring p53 function to p53-deficient cancer cells induces growth arrest and apoptosis (1, 2). Developing a method to safely and efficiently restore p53 activity to tumor cells in vivo has become a key goal in cancer research.

Missing or defective cellular proteins, such as p53 in many cancer cells, may be replaced via gene therapy or protein therapy. Gene therapy relies on the capacity of a cell to synthesize protein by using information encoded on exogenously provided DNA. Numerous viral and nonviral DNA delivery vectors have been tested, and p53 gene therapy has met with varying degrees of success both in vitro and in vivo (2). The primary factors limiting gene therapy at present include concerns over potential vector toxicity and immunogenicity, inefficient delivery of genes to cells, and relative instability of the transgene resulting in limited expression (3). As a potential alternative to gene therapy, protein therapy involves direct delivery of protein to the cells.

The discovery and development of protein transduction domains (PTD), peptides or fragments of proteins that carry cargo proteins into cells in an apparently receptor-independent manner, has facilitated a significant expansion in protein therapy. PTDs, such as the HIV Tat peptide, polyarginine peptides, and Fv [the single-chain fragment of anti-DNA autoantibody monoclonal antibody (mAb) 3E10], have delivered functional p53 to cancer cells in vitro (4–6). However, there have been no reports of successful full-length p53 protein therapy in vivo.

Fv possesses molecular characteristics that distinguish it as a unique PTD well suited to p53 protein therapy. First, Fv selectively localizes to cell nuclei. Induction of cell cycle arrest and apoptosis by p53 depends in part on its activation of target genes in the nucleus. Fv-mediated intranuclear delivery of p53 correctly positions p53 within the cell for transactivation of target genes. Second, given that Fv was originally derived from an antibody, Fv should not generate significant inflammation in vivo (7, 8). Inflammation or specific immune responses would hinder the therapeutic efficacy of p53 protein therapy. Whereas highly basic PTDs may generate significant inflammation on administration in vivo (9–12), Fv as a delivery vehicle for p53 protein therapy should bypass this potential obstacle.

We have previously shown that Fv-p53 selectively kills cancer cells and has no effect on nontransformed primary cells in vitro. Moreover, Fv-p53 effectively induces cell death in cancer cells with a variety of defects in p53, including absence of p53, mutations in p53, nuclear exclusion of p53, and overexpression of MDM2 (6). In the present study, we have extended the in vitro experiments to include additional control proteins to verify that Fv-p53 is the factor responsible for cell killing in cancer cell lines. Furthermore, we have tested Fv-p53 protein therapy in vivo and found it strikingly effective in preventing metastasis of colon carcinoma cells to the liver.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Plasmids
pPICZA-Fv-p53. cDNA encoding an Fv-p53 fusion protein was ligated into pPICZA as described previously (6).

pPICZA-Fv(R95Q)-p53. The pPICZA-Fv(R95Q)-p53 construct was generated by site-directed mutagenesis of the pPICZA-Fv-p53 construct using the QuikChange kit (Stratagene, La Jolla, CA) with mutagenesis primers 5'-CAGTAGTCAAGTAGTAACCCCTGCCTTGCACAG-3' and 5'-CATGTATTACTGTGCAAGGCAGGGGTTACTACTT-3'.

pPICZA-p53. cDNA encoding wild-type p53 was PCR amplified from the pPICZA-Fv-p53 construct using sense primer 5'-GAATTCATGCATCATCATCATCATCATGAGGAGCGGCAGTCAG-3' and antisense primer 5'-CTCGAGTCAGTCTGAGTCAGGCCC-3'. The PCR product was inserted into the pCR2.1 vector with use of the TA Cloning kit (Invitrogen, Carlsbad, CA). The p53 cDNA insert was liberated from pCR2.1-p53 by digestion with EcoRI and XhoI and ligated into EcoRI and XhoI sites in pPICZA.

pPICZA-Fv. cDNA encoding the single-chain fragment of mAb 3E10 was ligated into pPICZA as described previously (13).

Recombinant Proteins
Fv-p53, Fv(R95Q)-p53, wild-type p53, Fv, and X-33 control proteins were produced in and purified from Pichia pastoris and analyzed by SDS-PAGE followed by Western blot analysis as described previously (6). Typical yields of Fv-p53 and Fv(R95Q)-p53 were 30 µg from a 500 mL culture. Typical yields of wild-type p53 and Fv were 3 mg from a 500 mL culture. Concentrations of Fv-p53 were determined by an ELISA capture assay with anti-p53 antibodies and comparison with a standard curve.

Cell Lines
Skov-3 ovarian cancer and CT26.CL25 colon cancer cell lines were acquired from the American Type Culture Collection (Rockville, MD).

Nuclear Penetration Assay
Fv-p53, Fv(R95Q)-p53, or wild-type p53 (100 nmol/L) was applied to Skov-3 cells. As a positive control, 100 µmol/L Fv was also applied to the cells. After 1 h of incubation, cells were washed, fixed, and stained with anti-p53 pAb421 or anti-myc antibodies as described previously (6).

Microscopic Images
An Olympus IX70 inverted microscope with RC reflected light fluorescent attachment and MagnaFire SP Digital Imaging System (Olympus, Melville, NY) was used to acquire microscopic images of cells as described previously (14).

In vitro Cytotoxicity Assay
Fv-p53, Fv(R95Q)-p53, wild-type p53, or Fv (100 nmol/L) was applied to Skov-3 and CT26.CL25 cells. Control cells were incubated with X-33 yeast proteins. Twenty-four hours after addition of proteins to the cells, percentage cell death was determined by propidium iodide staining as described previously (6).

In vivo Liver Metastasis Model
A "hemispleen" model, as first described by Schulick et al. (15), was optimized. BALB/c mice at 10 weeks of age were purchased from The Jackson Laboratory (Bar Harbor, ME). The fur on the left flank was removed using clippers. The animals were anesthetized using halothane, and the surgical area was prepped with povidone iodine. A 1.0-cm to 1.5-cm incision was made in the left flank, and the peritoneal cavity was entered. The stomach was gently grasped to bring the entire spleen into view. Two medium vascular clips (Weck, Research Triangle Park, NC) were placed across the midbody of the spleen. The spleen was then divided between these clips, leaving two hemispleens, each with their own vascular pedicle. A 27-gauge needle was used to inject 1 x 10⁵ CT26.CL25 colon cancer cells into the inferior hemispleen. Before this injection, the syringes were preloaded with 250 µL HBSS. During the surgery, 50 µL of cell suspension were aspirated into the syringe, thus providing a saline flush after the cells were injected. Three minutes after the cell injection, a medium vascular clip was placed across the vascular pedicle and the inferior hemispleen was removed. Ten minutes later, the treatment or control solution was injected into the superior hemispleen in a similar manner. The hemispleen was left in place for a second injection 7 days later. The abdomen was then closed in a single layer using 5-0 Prolene suture. The animals were euthanized 2 weeks later, and the livers were examined. The whole liver was assigned a metastasis score of 0 (no gross metastasis), 1 (<1 cm² area of tumor), 2 (1–2 cm² area of tumor), 3 (>2 cm² area of tumor), or 4 (complete infiltration).

A "portal vein" model was also optimized (16). BALB/c mice at 10 weeks of age were used. The animals were prepped and anesthetized as described previously. An upper midline incision was made, and the peritoneal cavity was entered. The intestines were eviscerated and reflected to the right. A piece of warm saline-soaked gauze measuring 2 x 2 inches was placed over the intestines. A 31-gauge needle was used to inject 4 x 10⁵ CT26.CL25 colon cancer cells in 200 µL HBSS into the portal vein. A small piece of moist Gelfoam (Pharmacia Corp., Kalamazoo, MI) was then pressed over the injection site. Pressure was continued for 2 to 3 min, and the Gelfoam was left in place. The intestines were then returned to the abdomen, which was closed in one layer using 5-0 Prolene suture. The animal was then turned, and a second incision was made over the left flank. A small s.c. pocket was dissected, and then, the abdomen was entered. The whole spleen was used for injection of either Fv-p53 treatment or X-33 yeast protein control. After the injection, the whole spleen was placed into the s.c. pocket to facilitate subsequent injections. The spleen was held in position by closing the abdominal wall with 5-0 Prolene suture as described by Kasuya et al. (17). The skin was then closed in a separate layer using the same suture. A second spleen injection was done 7 days later via a minor surgery. The animal was anesthetized, and the left flank was prepped with povidone iodine. A small portion of the incision was opened, and the material was injected into the spleen under direct visualization. Seven days after the second injection, the animals were euthanized and a metastasis score (see above for criteria) was given to the left lobe of the liver that receives drainage from the splenic vein.

Statistics
A P value was determined by using a two-tailed Student's t test.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
The Fv fragment is required for nuclear delivery of p53. Fv-p53, Fv(R95Q)-p53, p53 alone, Fv alone, and X-33 control proteins were generated and purified from P. pastoris as described previously (Fig. 1 ). Fv(R95Q)-p53, abbreviated as R95Q, contains a mutation in Fv that renders the protein incapable of penetrating into the cells (13). X-33 proteins were eluted from Ni-NTA agarose (Qiagen, Valencia, CA) incubated with lysates of X-33 cells free of plasmids. The X-33 control showed the same pattern of proteins found in preparations of Fv-p53 and served as a control for protein impurities that copurify with Fv-p53 (Fig. 1). Fv-p53 and control proteins were tested for penetration into Skov-3 cells. Control cells treated with X-33 yeast proteins showed an absence of staining. Cells treated with Fv or Fv-p53 exhibited distinct nuclear staining representing nuclear penetration. As expected, cells treated with R95Q or p53 alone did not show nuclear staining. Because p53 alone failed to penetrate into Skov-3 cells, these results indicate that the Fv fragment is necessary for nuclear delivery of p53 (Fig. 2 ).

View larger version (11K): [in this window] [in a new window] [Download PPT slide]   Figure 1. Fv-p53, R95Q, Fv, p53, and X-33 control proteins. Fv-p53, Fv(R95Q)-p53, wild-type p53, Fv, and X-33 control proteins were produced in and purified from P. pastoris. Proteins were analyzed by SDS-PAGE followed by Western blot analysis with -p53 or -myc antibodies (Fv contains a myc tag). Ponceau S (Pon S) staining provides an approximation of purity of the recombinant proteins.

View larger version (15K): [in this window] [in a new window] [Download PPT slide]   Figure 2. Fv facilitates nuclear delivery of p53. Fv-p53, R95Q, p53, Fv, or X-33 yeast proteins (control) were tested for nuclear penetration in Skov-3 cells. Cells were washed, fixed, and stained with anti-p53 or anti-myc antibodies after 1 h of incubation with the proteins. Only cells treated with Fv-p53 or Fv exhibited nuclear staining, indicating that Fv facilitates and is required for nuclear delivery of p53. Bar, 5 µm.

View larger version (18K): [in this window] [in a new window] [Download PPT slide]   Figure 3. Fv-p53 kills cancer cells in vitro. Equimolar amounts of Fv-p53, R95Q, p53, Fv, or X-33 yeast proteins were applied to Skov-3 and CT26.CL25 cells in vitro, and the percentage of cells killed was determined 24 h later by propidium iodide staining. Columns, mean; bars, SD. A, Skov-3 cells: 93.8 ± 8.9% of Skov-3 cells were killed by Fv-p53 compared with 5.2 ± 4.3% by R95Q, 4.0 ± 2.8% by p53, 3.0 ± 1.4% by Fv, and 2.2 ± 1.5% by X-33 proteins. B, CT26.CL25 cells: 74.6 ± 24.1% of CT26.CL25 cells were killed by Fv-p53 compared with 13.8 ± 10.9% by R95Q, 3.0 ± 1.4% by p53, 2.5 ± 0.7% by Fv, and 2.5 ± 0.6% by X-33 proteins. C, concentrations ranging from 0 to 100 nmol/L Fv-p53 were tested on CT26.CL25 cells. Fv-p53 killing of CT26.CL25 cells was dose dependent.

Fv-p53 prevents liver metastasis in vivo. A liver metastasis model, generated by injecting CT26.CL25 colon carcinoma cells into BALB/c mice, was used to test the efficacy of Fv-p53 protein therapy in vivo. The first mouse experiment used the "hemispleen" method to optimize the timing of Fv-p53 delivery after injection of the cancer cells. CT26.CL25 colon carcinoma cells were given to 12 BALB/c mice, which were divided into four groups. Mice in each group received two hemispleen injections of 100 nmol/L Fv-p53 or control medium. The first injections of Fv-p53 or control medium were made 10 min after administration of the CT26.CL25 cells, whereas the second injections occurred 1 week later. Mice in group 1 received control medium for both injections. Mice in group 2 received Fv-p53 for the first injection and control medium for the second injection. Group 3 mice received control medium for the first injection and Fv-p53 for the second injection. Finally, group 4 mice received Fv-p53 for both the first and second injections. Two weeks after the second injections, the mice were euthanized and the livers were examined to determine the extent of tumor burden. The mice in group 1 had an average metastasis score of 2.7 ± 0.5. In contrast, group 4 had an average metastasis score of 1.0 ± 0.0, indicating a decrease in tumor burden in the treated mice. Mice in groups 2 and 3 had scores of 0.7 ± 0.9 and 2.0 ± 0.8, respectively (Table 1 ). This shows that Fv-p53 seems to have an effect on the prevention of liver metastasis, and as expected, early treatment was more effective than delayed treatment.

View larger version (72K): [in this window] [in a new window] [Download PPT slide]   Figure 4. Determination of metastasis scores. Two weeks after the injection of CT26.CL25 cells into BALB/c mice, mice were sacrificed and assigned metastasis scores based on the following criteria: 0, no liver metastasis; 1, minimal infiltration (<1 cm2 area of metastasis); 2, mild to moderate infiltration (1–2 cm2 area of metastasis); 3, severe infiltration (>2 cm2 area of metastasis but the liver was not entirely infiltrated); and 4, complete infiltration. Examples of mice receiving each score in the representative images.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

p53 therapy presents a potentially elegant solution to the problem of metastatic disease in that small doses of p53 induce growth arrest and apoptosis in transformed cells but do not seem to adversely affect normal cells (6). It also has the profound advantage of likely being applicable to greater than half of all tumor cells. The obvious question to be answered pertains to the best means of delivering p53 to cells.

Protein therapy could be effective in treating nearly any protein deficiency disease but is particularly well suited to the treatment of cancer. Whereas patients with chronic diseases might require continuous replacement therapy, cancer patients would potentially require only a limited number of doses of p53 to eliminate cancer cells. Furthermore, p53 is functional at a very low intracellular concentration, and the frequency and duration of p53 infusions could be easily modified to minimize side effect profiles.

The Fv fragment of mAb 3E10 is an ideal transport vehicle for p53 protein therapy. Fv specifically delivers most cargo proteins to the nucleus and should promote less inflammation than other PTDs (7, 8). In the present study, no side effects of Fv-p53 therapy were observed in any of the experimental mice. Fv also has a short half-life inside the cells,⁶ and previous studies using single-chain Fv fragments to visualize tumors in vivo found that Fv fragments localize into the tumor cells more readily than normal cells and are rapidly cleared from the body (19, 20). The propensity of Fv fragments to localize to tumors would facilitate delivery of p53 to target tissues, and if side effects become a concern, the short half-life of Fv and rapid plasma clearance of Fv fragments would aid in limiting therapy duration.

The timing of Fv-p53 treatment in relationship to the development of metastatic disease seems to be important. In our mouse model, Fv-p53 given 10 min after injection of cancer cells seemed to suppress metastasis to the greatest extent (Table 1). Although the mice receiving Fv-p53 at 7 days seemed to have a larger metastatic burden compared with those receiving an initial dose of Fv-p53 at 10 min, there was still a suggestion that they had a lower metastasis score compared with those that received the control injection at both times. The ability of Fv-p53 to suppress metastasis whether given 10 min or 1 week after administration of cancer cells suggests that Fv-p53 may be able to kill both recently metastasized cells and established tumor cells.

The second in vivo experiment showed that Fv-p53 treatment had a profound effect on liver metastasis. Control mice treated with X-33 yeast proteins had severe to complete tumor infiltration of the liver, whereas mice treated with Fv-p53 had minimal to no liver metastasis. This result was not only statistically significant but also readily apparent on gross observation of the livers from control and Fv-p53–treated mice (Table 2; Fig. 4). This shows that Fv-p53 has activity even in the setting of a very large metastatic burden.

Future studies will focus on specifically quantifying Fv-p53 antitumor activity, doing survival studies, and testing the ability of Fv-p53 to kill established, solid tumors. Technical studies will also be done to increase the yield and purity of Fv-p53. The primary significance of this work is that, for the first time, full-length p53 protein therapy is effective in vivo, suggesting that Fv-p53 could potentially be developed into an effective cancer therapy.

	Acknowledgments

 
Grant support: Veterans Affairs grant (R.H. Weisbart) and Department of Surgery, Loma Linda University seed grant (M.E. Reeves).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Marsha Fillipova for quantification of p53 proteins and Dr. Joseph Gera for critical reading of the manuscript.

	Footnotes

 
Note: J.E. Hansen and L.K. Fischer are cofirst authors. R.H. Weisbart and M.E. Reeves are cosenior authors.

⁶ J.E. Hansen et al., unpublished data.

Received 10/13/06. Accepted 12/ 7/06.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Vousden KH. p53: death star. Cell 2000;103:691–4.[CrossRef][Medline]
2. Nielsen LL, Maneval DC. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998;5:52–63.[Medline]
3. Kodama K, Katayama Y, Shoji Y, Nakashima H. The features and shortcomings for gene delivery of current non-viral carriers. Curr Med Chem 2006;13:2155–61.[CrossRef][Medline]
4. Ryu J, Lee HJ, Kim KA, et al. Intracellular delivery of p53 fused to the basic domain of HIV-1 Tat. Mol Cells 2004;17:353–9.[Medline]
5. Takenobu T, Tomizawa K, Matsushita M, et al. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther 2002;1:1043–9.[Abstract/Free Full Text]
6. Weisbart RH, Hansen JE, Chan G, et al. Antibody-mediated transduction of p53 selectively kills cancer cells. Int J Oncol 2004;25:1867–73.[Medline]
7. El-Amine M, Hinshaw JA, Scott DW. In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FvR or a mutated IgG Fc fragment. Int Immunol 2002;14:761–6.[Abstract/Free Full Text]
8. Zambidis ET, Scott DW. 1996 Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci U S A 1996;93:5019–24.[Abstract/Free Full Text]
9. Lai Y, Du L, Dunsmore KE, Jenkins LW, Wong HR, Clark RS. Selectively increasing inducible heat shock protein 70 via TAT-protein transduction protects neurons from nitrosative stress and excitotoxicity. J Neurochem 2005;94:360–6.[CrossRef][Medline]
10. Pu H, Tian J, Flora G, et al. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci 2003;24:224–37.[CrossRef][Medline]
11. Moulton HM, Hase MC, Smith KM, Iversen PL. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev 2003;13:31–43.[CrossRef][Medline]
12. Toborek M, Lee YW, Pu H, et al. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem 2003;84:169–79.[CrossRef][Medline]
13. Weisbart RH, Wakelin R, Chan G, Miller CW, Koeffler PH. Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53. Int J Oncol 2004;25:1113–8.[Medline]
14. Weisbart RH, Baldwin R, Huh B, Zack DJ, Nishimura R. Novel protein transfection of primary rat cortical neurons using an antibody that penetrates living cells. J Immunol 2000;164:6020–6.[Abstract/Free Full Text]
15. Jain A, Slansky JE, Matey LC, Allen HE, Pardoll DM, Schulick RD. Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol 2003;10:810–20.[CrossRef][Medline]
16. Cai SR, Garbow JR, Culverhouse R, et al. A mouse model for developing treatment for secondary liver tumors. Int J Oncol 2005;27:113–20.[Medline]
17. Kasuya H, Kuruppu HK, Donahue JM, Choi EW, Kawasaki H, Tanabe KK. Mouse models of subcutaneous spleen reservoir for multiple portal venous injections to treat liver malignancies. Cancer Res 2005;65:3823–7.[Abstract/Free Full Text]
18. Mehra R, Burtness B. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opin Biol Ther 2006;6:951–62.[CrossRef][Medline]
19. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402–8.[Abstract/Free Full Text]
20. Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 1993;53:3776–83. Erratum in: Cancer Res 1993;53:5832.[Abstract/Free Full Text]

This article has been cited by other articles:

				N. Kurata, T. Shishido, M. Muraoka, T. Tanaka, C. Ogino, H. Fukuda, and A. Kondo Specific Protein Delivery to Target Cells by Antibody-displaying Bionanocapsules J. Biochem., December 1, 2008; 144(6): 701 - 707. [Abstract] [Full Text] [PDF]

				J. E. Hansen, C.-M. Tse, G. Chan, E. R. Heinze, R. N. Nishimura, and R. H. Weisbart, Intranuclear Protein Transduction through a Nucleoside Salvage Pathway J. Biol. Chem., July 20, 2007; 282(29): 20790 - 20793. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hansen, J. E. Articles by Reeves, M. E. Search for Related Content PubMed PubMed Citation Articles by Hansen, J. E. Articles by Reeves, M. E.